

How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature

Dhananjay Yadav^{1,*}, Nidhi Puranik^{2,*}, Anju Meshram^{3,*}, Vishal Chavda⁴, Peter Chang-Whan Lee⁵, Jun-O Jin⁶

¹Department of Life Science, Yeungnam University, Gyeongsan, 38541, South Korea; ²Biological Sciences Department, Bharathiar University, Coimbatore, Tamil Nadu, 641046, India; ³Department of Biotechnology, Kalinga University, Naya Raipur, Chhattisgarh, India; ⁴Department of Pathology, Stanford School of Medicine, Stanford University Medical Center, Stanford, CA, 94305, USA; ⁵Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, South Korea; ⁶Department of Microbiology, University of Ulsan College of Medicine, Seoul, 05505, South Korea

*These authors contributed equally to this work

Correspondence: Peter Chang-Whan Lee, Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, South Korea, Email pclee@amc.seoul.kr; Jun-O Jin, Department of Microbiology, University of Ulsan College of Medicine, Seoul, 05505, South Korea, Email junojin@amc.seoul.kr

Abstract: Cancer is a broad term for a group of diseases involving uncontrolled cell growth and proliferation. There is no cure for cancer despite recent significant improvements in screening, treatment, and prevention approaches. Among the available treatments, immunotherapy has been successful in targeting and killing cancer cells by stimulating or enhancing the body's immune system. Antibody-based immunotherapeutic agents that block immune checkpoint proteins expressed by cancer cells have shown promising results. The rapid development of nanotechnology has contributed to improving the effectiveness and reducing the adverse effects of these anti-cancer immunotherapeutic agents. Recently, engineered nanomaterials have been the focus of many state-of-the-art approaches toward effective cancer treatment. In this review, the contribution of various nanomaterials such as polymeric nanoparticles, dendrimers, microspheres, and carbon nanomaterials in improving the efficiency of anti-cancer immunotherapy is discussed as well as nanostructures applied to combination cancer immunotherapy.

Keywords: nanotechnology, combination therapy, cancer therapy, engineered nanomaterials, nanotoxicity, synergistic therapy

Introduction

Cancer is a major cause of morbidity and mortality around the world in recent years.^{1,2} The 5-year relative survival rate for all cancer-related malignancies diagnosed between 2009 and 2015 was 67% based on data reported in Cancer Statistics, 2020.² Lack of early tumor diagnosis and effective therapies remain major problems to be addressed. The conventional cancer treatment approach involves surgical intrusion, phototherapy, and chemotherapy to diminish tumors and prevent cancer metastasis. Chemotherapy is frequently associated with side effects induced by off-target toxicity as a result of drug non-specificity.³ Rapid advancements in nanomedicine have led to the implementation of novel therapeutic nanotechnology-based applications and improved patient care.⁴ Cancer immunotherapy in combination with functionalized nanoparticles has emerged as an alternative treatment option that is highly effective.^{5,6} The relevance of stimuli-responsive nanosystems and nanomaterial-based cancer immunotherapy should not be underestimated.

Cancer immunotherapy is a new type of treatment that stimulates the immune system to attack cancer cells.^{7,8} Despite the existence of various immunotherapeutic drugs to treat cancer, low patient response rates and the possibility of immune-related side effects are two important obstacles to successful treatment. The development of activatable cancer immunotherapies can help to address both of these challenges. Due to the fast evolution and integration of

nanotechnology, material science, and biomedical engineering, different nanomaterials have been developed and utilized in the field of cancer immunotherapy.^{9–11} Activatable immunotherapeutic nanoagents are the result of the convergence of stimuli-responsive nanomedicine and immunotherapy.^{12,13} Immunotherapeutic nanoagents require activation via internal or external stimuli to function,^{14,15} rewire the tumor microenvironment, and activate anticancer immunity, while lowering the risk of immune-related side effects. Immunotherapeutic nanoagents exhibit advantages such as optimal biodistribution, selective cell targeting, and regulated immune activation.

Nanomedicines contribute to the safe and effective use of immunotherapies in clinical trials due to their controlled delivery and modular flexibility. The convergence of nanomedicine and immunotherapy, with an emphasis on molecular and nanoengineering approaches to cancer immunotherapy, is the subject of this review. Specifically, this article discusses different strategies of cancer immunotherapy and the role of nanoparticles in enhancing the immunotherapeutic effect of different immunomodulatory drugs with a focus on activatable immunotherapeutic nanoagents, as well as the advantages and obstacles of clinical translation.

Where Do We Stand in Cancer Immunotherapeutics?

In cancer immunotherapy, tumor cells are eliminated by manipulating the immune system to produce long-lasting anticancer immune responses. Adoptive T cell therapy and chimeric antigen receptor (CAR)-T cell therapy are two of the most popular immunotherapy modalities today. Adoptive cell therapy (ACT) is another common immunotherapy in which effector immune cells, primarily autologous T cells with CAR and T cell receptors (TCR), are sampled from patients, activated, and expanded ex vivo before being returned to the patients in expectation of a therapeutic outcome. Clinical trials using CAR-T cells have yielded impressive and encouraging results, particularly in patients with B-cell acute lymphoblastic leukemia, although their impact on solid tumors has been muted. Adoptive T cell therapy, however, has been associated with problems such as cytotoxicity, poor in vivo persistence, and cytokine release syndrome (CRS).¹⁶ Therefore, achieving high selectivity against cancer cells is crucial in immunotherapy. Various cancer treatment and management strategies, such as CAR-T cell therapy, cell-assisted delivery, checkpoint blockade, and cancer vaccines are illustrated in Figure 1.

How Advanced are Cancer Therapeutic Vaccines?

Vaccines are used to deter future infections by inducing the production and activation of memory cells. To create memory responses, the overall immune response mechanism must be activated starting with the antigen-presenting cells (APCs).




Figure 1 Strategies for cancer management and treatment, currently in use. Data from these studies.^{16–18}

Among APCs, dendritic cells (DCs) are well-known direct inducers of T cell activity. DCs present phagocytic antigens on their surface by utilizing either an MHC class II extracellular antigen or an MHC class I intracellular antigen. Antigens bound to MHC class II are recognized by CD4 T cells, and antigens bound to MHC class I are delivered to CD8 T cells to activate respective cells, which are subsequently differentiated into helper T (Th) cells and cytotoxic T lymphocytes (CTLs), respectively. Therefore, the vaccines utilizing cancer antigens induce antigen-specific T cell immunity which can be exploited for cancer treatment.

The immune system's ability to distinguish between self-antigens that are normally expressed on the surface of healthy cells and those that are abnormally expressed on cancer cells is key for cancer vaccine development. The key benefits of cancer vaccines are their moderate toxicity, rapid response to tumor-associated antigen (TAA) exposure, induction of extremely precise adaptive immune responses, and establishment of immunologic memory while controlling or removing residual disease.¹⁷ However, for a therapeutic vaccine to be effective in cancer treatment, DC-mediated immune activity is required. Cancer antigens are derived from normal cells and do not produce an immune response in our body. Thus, immune stimulatory molecules in the form of appropriate adjuvants must be combined with cancer antigens to induce DC-mediated antigen-specific T cell immunity.

What is the Potential of Immune Checkpoint Inhibitors?

A novel class of cancer medicines known as immune checkpoint inhibitors has demonstrated remarkable success over a relatively short period of clinical testing. These medications have shown a sharp rise in clinical use since their first approval in 2011 for metastatic melanoma.¹⁸ Immune checkpoints are receptors expressed on cells of the immune system; they allow for the dynamic regulation of immune homeostasis and play an important role in T cell activity. Programmed cell death protein 1 (PD-1) and PD-1 ligand (PD-L1) are immune checkpoint proteins expressed on T lymphocytes, tumor cells, and myeloid cells that have invaded tumors.¹⁹

Many aspects of cancer therapy have been revolutionized by the recent introduction of immune checkpoint inhibitor (CPI) antibodies, although their efficacy remains restricted since several patients fail to respond for unspecified reasons. Local signaling has been shown to establish immunosuppressive microenvironments within tumors in several human and animal studies. Emerging evidence suggests that introducing immunostimulatory molecules into tumors can have therapeutic effects. Such molecules in the form of carrier nanoparticles provide a realistic technique for increasing CPI distribution and efficacy.²⁰

What is the Potential of Natural Killer (NK) Cell-Mediated Immunotherapy?

NK cells are part of the innate immune system's lymphoid cells and play a crucial role in immunological surveillance. NK cells act as a link between innate and adaptive immunity, while their infiltration into tumor areas is positively correlated with increased patient survival. Target cells are exposed to the cytolytic effect of NK cells, which induce apoptosis.²¹ NK cells are toxic to cancer cells without causing any sensitization to cancer antigens. Similar to CTLs, NK cells also secrete granules such as perforin and granzymes to lyse cancer cells. In addition, NK cells secrete interferon-gamma (IFN- γ) and tumor necrosis factor-alpha (TNF- α) to trigger adaptive immune responses. Due to the immunostimulatory function and anti-cancer effect of NK cells, their immunotherapeutic potential is being actively investigated. Current challenges for using NK cells in cellular immunotherapy include loss of NK cell cytotoxic ability and a decline in the number of activating receptors, which lead to a reduction in long-term effectiveness.

What Do We Know About the Tumor Microenvironment (TME)?

The tumor microenvironment (TME), a heterogeneous, complex organization consisting of tumor, stroma, and endothelial cells, is characterized by the crosstalk between the tumor and innate and adaptive immune cells. Over the past decade, immune cells in the TME have been demonstrated to be essential for both hindering and driving tumor growth. The role of T cells in this process has been extensively studied. Numerous studies have suggested that B cells play a crucial part in anticancer immunity. However, the TME contains a wide variety of B cell types, including memory and terminally differentiated plasma cells as well as naive B cells.²²

TME induces the growth of cancer cells while preventing the attack from immune cells by tricking them to recognize cancerous tissue as peripheral tissue. Regulatory immune cells that are directly involved in this action include regulatory T cells, Type 2 macrophages, and myeloid-derived suppressor cells.

What is the Potential of Regulatory T Cells (Tregs) in Cancer Immunotherapy?

All organs, including the ones in the circulatory system, contain specialized immune cells called Tregs. Tregs maintain immunological homeostasis and regulate countermeasures to inhibit excessive immune activation to avoid autoimmune responses.²³ Activated immune cells not only remove invading pathogens but can also damage normal cells. Tregs help to regulate the immune system after it is activated. Since Tregs contribute to immune suppression, they play crucial roles in hindering antitumor immunity. The majority of solid tumors contain Tregs that inhibit the antitumor immune response, which can cause immunosuppression and result in a poor prognosis. By suppressing self-reacting T cells, avoiding autoimmunity, and regulating chronic inflammatory conditions, Tregs actively contribute to the preservation of immunological self-tolerance.²⁴ Inside the TME, naive T cells can differentiate into Tregs. As a result of their strong immunosuppressive ability, Tregs inhibit anti-cancer immunity, favoring the growth of cancer cells. Therefore, removing or inhibiting the activity of Tregs in the TME is a potential strategy for cancer immunotherapy.

What is the Role of Macrophage Polarization in Cancer Immunotherapy?

Due to their great phenotypic variability and functional diversity, macrophages are key players in both innate and adaptive immunity. Furthermore, they are important for immunology, tissue and systemic inflammation, and tissue regeneration.²⁵ Macrophages constitute more than 50% of the tumor mass in solid tumors, while tumor-associated macrophages (TAMs) can originate from both local and circulating progenitor monocytes.²⁶ TAMs participate in the formation of the tumor microenvironment and play a major role in the TME functions.²⁷ Inside the TME, cancer cells use various substances such as IL-10, CCL2/3/4/5/7/8, VEGF, CXCL12, and the platelet-derived growth factor (PDGF), to transform type 1 macrophages (M1) into type 2 macrophages (M2). TME M2 macrophages express various cytokines, chemokines, and growth factors that contribute to cancer potential, growth, and metastasis and lead to cancer exacerbation. Therefore, converting M2 macrophages into M1 macrophages is being investigated as a strategy to prevent cancer growth and improve immunotherapy efficiency.

What is the Role of Myeloid-Derived Suppressor Cells (MDSCs) in Cancer Immunotherapy?

MDSCs include a diverse population of immature myeloid cells that have immunosuppressive roles in tumor-bearing mice or humans with malignancies; they suppress T cell activity and encourage tumor immune evasion in the TME.^{28,29} MDSCs can be divided into two main subsets, polymorphonuclear MDSCs and monocytic MDSCs. Both types of MDSCs are observed inside a tumor. Activated MDSCs promote cancer growth via several mechanisms, including immune evasion, angiogenesis, and the formation of a metastatic environment. Among these, immune evasion is the most common function of MDSCs.

MDSCs express high levels of inducible nitric oxide synthase (iNOS), leading to the production of nitric oxide (NO). The function of NO on T cells has been well studied and includes inhibition of activation, proliferation, and differentiation of T cells. Moreover, the MDSC-produced NO induces apoptosis in T cells, and MDSCs also produce reactive oxygen species (ROS) that inhibit T cell function (Figure 2). As T cells are the main cells that exhibit cytotoxicity against cancer cells in immunotherapy, eliminating MDSCs can be a strategy for enhancing cancer immunotherapy.

What are the Potential Carriers for Drug Delivery in Cancer Therapy?

Nanoparticles

Drugs with low solubility are difficult to formulate using traditional methods due to issues such as the slow onset of action, low oral bioavailability, dose proportionality, inability to maintain steady-state plasma levels, and undesirable side effects. Therefore, traditional formulations may lead to over- or under-medication, as well as poor patient compliance.^{30,31} To overcome this problem, nanotechnology is being widely utilized as a promising technique for developing drug delivery systems, particularly for medications with poor solubility, limited permeability, insufficient bioavailability, and other biological shortcomings (Figure 3). Various theragnostic biodegradable carriers, liposomes, carbon nanoparticles, quantum




Figure 2 Role of MDSCs in tumor growth by targeting different immunological cells. Data from these studies.^{24,29}




Figure 3 Role of different kinds of nanoparticles to increase the pharmacokinetic properties of drugs in cancer treatment. Data from these studies.^{30,31,36}

dots, polymeric micelles, dendrimers, and metallic nanoparticles are examples of nanosystems used for drug delivery in cancer treatment.^{32–36} Table 1 provides a quick overview of the various nanomaterials employed in cancer therapy.

Liposomes

Liposomes are colloidal or nano-particulate carriers with a size range of 80–300 nm. Among the various types of nanoparticles, liposomes are the first and most well-established drug-delivery vehicles, with a plethora of clinical products in the market today. Liposomes are bilayer spherical vesicles composed of amphiphilic lipid molecules widely used in cancer therapy.^{56–58} Their advantages include effectiveness, biocompatibility, non-immunogenicity, increased solubility of therapeutic agents, and capacity to encapsulate a wide range of medications.⁵⁹ Furthermore, liposomes have demonstrated remarkable therapeutic potential as payload carriers for delivery to specific sites.⁶⁰ Overall, liposome-mediated drug delivery systems (DDS) improve the therapeutic payload's pharmacokinetic and pharmacodynamic profiles, stimulate controlled and sustained drug release, and have negligible systemic toxicity compared to free DDS.⁶¹

Polymeric Nanoparticles (PNPs)

PNPs have sparked a lot of interest in various fields because of their ability to modify drug activity, exhibit controlled drug release, and improve drug adhesivity or penetration time in the skin, which are all properties that render them ideal

Table 1 Characteristics of Various Nanomaterials Used in Cancer Therapy

Nanomaterial Category	Characteristic Structure	Advantages	Limitation	References
Liposomes	Lipid bilayer	Biocompatibility, non-immunogenicity, increase solubility of associated molecule	Less stable, hydrophilic drug	[37–39]
Polymeric nanoparticles (Nanospheres/ Nanocapsules)	Polymer-based NPs having lipophilic core	High stability, low outflow of drugs	Toxic when administered intravenously	[40,41]
Dendrimers	Three-dimensional branched polymers	Presence of functional group, enhances the solubility and availability of hydrophobic drugs	Quick elimination from the precorneal region	[42,43]
Microspheres	Polymeric	Large surface area, high absorption rate on surface and long-term bio-availability of drugs	Difficult to design	[44,45]
Gold nanoparticles	Surface of gold atom has negatively charged group	High surface-to-volume ratio, hydrophilic in nature, surface modification is easy	Toxicity, quick elimination	[46,47]
Carbon nanoparticles (Carbon nanotubes)	Fullerenes or one or more graphene sheets	High cell penetration abilities, high stability, flexible to modify the surface and function	Non-biodegradable, cytotoxic, less solubility in water	[48,49]
Metallic nanoparticles (MNPs)	Metallic property containing nanoparticles, wire, rods, and capsules	Antibacterial properties, magneto-optical response	Related toxicity	[50,51]
Polymeric micelles (PMs)	Core/shell lipid based self-assembled structure	Easy synthesis, delay and control drug release, variability, give stability to hydrophobic drug	Depolymerization at dilution	[52–54]
Inorganic Non-metallic Nanomaterials	Unique size with adjustable Pore size	More drug loading capacity because of the large surface area, suitable pore volume	Very slow biodegradation, high degree of toxicity of NPs	[55]

Abbreviation: NPs, nanoparticles.

for cancer drug applications.^{62,63} PNPs are nanocapsules or nanospheres with an average diameter of fewer than 1 μm , depending on their composition. PNPs are manufactured by two methods: dispersion of prepared polymers and monomer polymerization. PNPs are primarily used in targeted delivery systems as drug carriers for cancer therapy because of their favorable properties including being decomposable, biocompatible, non-toxic, extended circulation, and having an extensive payload capacity for encompassing therapeutic molecules.⁶⁴

Polymeric Micelles (PMs)

PMs have been widely used in pre-clinical trials to treat cancer patients by delivering poorly soluble chemotherapeutic drugs.⁶⁵ PMs are spherical nanoscopic core/shell structures generated by the self-assembly of amphiphilic polymers with a mean diameter of 10–100 nm. They have grown in popularity as a result of numerous advantageous properties, including their ability to solubilize a variety of low-solubility pharmaceutical agents, biocompatibility, vitality, and propensity to accumulate in pathological areas.^{66,67} Various polymeric combinations are used for optimum loading, stability, and systemic circulation, and thereby contribute to the recognition of target cancer tissue by the wide range of polymeric blocks utilizing both hydrophobic and hydrophilic nanomaterials.⁵⁴ Furthermore, PMs are easily customized by altering the number of monomers in each polymeric chain.

Dendrimers

Dendrimers are a new type of polymer with easily modifiable structures and nanometric dimensions. Dendrimers are globular macromolecules that range in size from 1 to 100 nm and include domains such as a central core, a hyperbranched mantle, and a corona with reactive functional groups on the periphery.⁶⁸ Dendrimers are virtually perfect spherical nanocarriers with predictable features due to the high level of control over the synthesis of their dendritic architecture. Many different types of dendrimers have been effectively developed for drug delivery, including polyamidoamine (PAMAM), poly(propylene imine) (PPI), poly(glycerol-co-succinic acid), poly-L-lysine (PLL), melamine, triazine, poly(glycerol), poly[2,2-bis(hydroxymethyl)propionic acid], poly(ethylene glycol) (PEG), carbohydrate-based, and citric dendrimers. PAMAM and PPI are the most studied vectors for medical applications.⁶⁹

Microspheres

Microspheres can be delivered using a syringe needle and are used to encapsulate a wide range of medications including tiny molecules, proteins, and nucleic acids. Polymeric microspheres are attractive carriers for numerous controlled delivery applications because of their ability to encapsulate a range of medications, their biocompatibility, high bioavailability, and prolonged drug release characteristics.⁷⁰

Carbon Nanoparticles and Carbon-Based Nanosystems (CBNs)

Carbon-based nanoparticles (NPs) have attracted interest because of their unique structural dimensions and physico-chemical features.⁷¹ Carbon nanotubes (CNTs) and carbon nanohorns (CNH) are two types of carbon nanocarriers utilized in DDS. CNTs have a unique design generated by rolling single or multiple layers of graphite with large surface areas and good electrical and thermal conductivity. CBNs such as graphite (GT), fullerenes, CNTs, graphene oxide (GO), reduced GO (rGO), and GO-Ag NP nanocomposites have been extensively used as drug delivery carriers.^{72,73} These materials have great drug-loading capacity, post-chemical modification, increased biocompatibility, and decreased immunogenicity because of their high optical activity and large multifunctional surface area.⁷⁴

Metallic Nanoparticles (MNPs)

Metallic nanoparticles have a wide range of properties that make them excellent drug-delivery vehicles. Easy handling with the aid of an external magnetic field, the ability to apply passive and active drug administration techniques, visibility (MNPs are used in MRI), and improved absorption by the target tissue resulting in efficient therapy at therapeutically relevant concentrations are a few manifestations of MNP effectiveness.⁷⁵ MNPs have been extensively used both in biological and engineering studies. MNPs can be manufactured and modified with different chemical functional groups, resulting in a variety of biomedical applications.⁷⁶ MNPs range in size from 1 to 100 nm and exhibit optical properties dependent on their form and size. MNPs employed in biological applications include Ag, Au, palladium, platinum, zinc oxide, iron oxide, and in various forms such as nanoshells and nanocages, to name a few.⁶²

Cancer Immunotherapy Using Nanoparticles

Current trends in cancer treatment involve the enhancement of immunotherapy effectiveness by combining two or more treatment methods. One example of combination therapy is based on immunotherapy and nanomaterials. Nanomaterials have the advantage of enhancing the action of various drugs via their interaction mediated by a variety of functional groups. This was demonstrated in a study where bromelain encapsulated gold nanoparticles (B-AuNPs) formed a conjugate with cisplatin (CIS) and doxorubicin (DOX), resulting in a considerable increase in the efficiency of both chemotherapy drugs. The enhanced inhibitory effect of the combinations compared to single drug-based chemotherapy show that the use of combination medicines (B-AuNPs conjugated with CIS and DOX) can be extremely helpful in osteosarcoma treatment.⁷⁷ Shiva Prasad Kollur et al studied luteolin-fabricated ZnO nanostructures exhibiting PLK-1 mediated anti-breast cancer activity, which was superior to the activity exerted by each of the two components when tested individually.⁷⁸

Curcumin is an active ingredient of dietary spice that has various pharmacological properties including anticancer activity and has been used recently in breast cancer treatment. Curcumin conjugated with poly-glycerol-malic acid-dodecanedioic acid (PGMD) NPs resulted in a formulation with increased anticancer activity compared to that of curcumin alone.⁷⁹ Similar results were reported in a drug delivery study with Diosgenin-loaded PGMD NPs, which displayed a significantly higher anticancer potential compared to the free drug.⁸⁰ Another study conducted by the same group showed that PLGA nanoparticles conjugated with PEI-EPI-PTX represent a feasible anti-cancer strategy with clinical advantages and may one day provide lung cancer patients with an effective treatment.⁸¹

Next, we will discuss nanomaterials used alone in therapeutic trials or combination with immunotherapy methods.

Induction of Antigen-Specific Immunity by Nanomaterials

Nanoparticles have the potential to initiate and influence immune responses by targeting APCs and delivering coordinated signals that can prompt an antigen-specific immune activation.⁸² New formulations of NPs that can specifically calibrate the immune response have been made possible by innovative methods in NP design that enable them to interact with particular cellular and molecular targets.⁸³ Yang et al coated R837-loaded PLGA nanoparticles (NP-R) with cancer cell membranes and then modified them in the mannose moiety (NP-R@M-M) to increase their therapeutic effect.⁸⁴

Immune Checkpoint Blockade Contained Nanoparticles

Immune checkpoint blockade (ICB) therapy has shown remarkable success in treating various human cancers, including melanoma and lung cancer by targeting PD-1 and its ligand.⁸⁵ However, the response rate of this treatment remains relatively low in most cases.⁸⁶ To enhance the success rate of ICB therapy, CPIs were combined with NPs shown to play a critical role in target-specific drug delivery. The encapsulation of immune CPI into NPs not only elevated the immunotherapeutic responses but also decreased off-target effects.^{87,88} A recent study demonstrated high efficacy and immunotoxicity of small-sized silver NPs combined with an anti-PD-1 monoclonal antibody (mAb) for the treatment of melanoma in both immunodeficient and immunocompetent mouse models.⁸⁹ Based on several studies, the creation of peptide-based nanocomplexes containing immunostimulatory oligonucleotides greatly improved the effectiveness of selected drugs to trigger toll-like receptor activation.^{90–93} In mouse cancer models, the administration of immunostimulatory nanocomplexes containing CpG oligonucleotides produced antitumor effects and improved the efficacy of CPI antibody therapy, allowing for a significant reduction in the dose needed to achieve therapeutic effects.^{20,94}

Chemoimmunotherapy

Chemotherapy and immunotherapy are the third and seventh anticancer therapeutic cornerstones, respectively. Surgery and therapies including radiation, hormone, and cell therapy are the most common post-cancer treatments.⁹⁵ Combinations of basic chemotherapy and immunotherapy may achieve additive or even synergistic antitumor therapeutic effects by attacking different parts of tumor biology and overcoming their own limits.^{96,97} Wang et al used an engineered therapeutic agent to develop a chemoimmunotherapy-based combinatorial method. In tumor-bearing mice, a hydrogel scaffold containing an ROS-sensitive moiety could locally distribute gemcitabine (GEM) and an anti-programmed death ligand antibody (α PDL1) with different kinetics promote the formation of an immunogenic tumor phenotype and result in immune-mediated tumor rejection.⁹⁸

Min et al created eco-friendly and biocompatible antigen-capturing nanoparticles (AC-NPs) that ameliorated cancer immunotherapy outcomes. Delivering tumor-specific proteins to APCs via AC-NPs has been reported to dramatically boost the efficacy of PD-1 administration in the B16F10 melanoma model, resulting in a 20% increase in cure rate when compared to that of the control.⁹⁹ AC-NPs aided the proliferation of CD8⁺ cytotoxic T cells and enhanced the ratios of CD4⁺/Treg and CD8⁺/Treg.⁹⁹ This could be considered a unique nanotechnology-based technique for improving cancer immunotherapy.⁹⁹

Photoimmunotherapy

Photoimmunotherapy (PIT) is a well-known cancer treatment therapy that combines phototherapy with immunotherapy by injecting a conjugate photosensitizer (IR700) and a mAb to target an expressed antigen on the surface of cancer cells.

PIT improves the immune response in the treatment of residual tumors and metastatic cancer.¹⁰⁰ However, complete eradication of the tumor is hindered by the non-specific delivery of immunotherapeutic molecules. NPs play a crucial role in overcoming this problem by acting synergistically with PIT and acting as carriers for immunotherapeutic drugs.¹⁰¹ Photothermal therapy (PTT) has the potential to directly trigger tumor cell apoptosis, and it can be paired with immune system adjustments to boost immune response levels. In previous studies, we have shown that PIT can treat 1st transplanted tumor and prevent 2nd challenged metastatic lung cancer growth in mice (Figure 4). The 1st tumor was treated by PTT, which induced the generation of tumor cell antigens. Furthermore, NPs containing immune stimulatory molecules promoted DC activation, which induced cancer antigen-specific immune responses and prevented 2nd tumor challenge in the mice.^{102–106} Chen et al manufactured a PLGA nanoparticle to co-load indocyanine green (ICG) and imiquimod (R837, a Toll-like receptor 7 agonist) for PDT and immune response activation.¹⁰⁷

Combination Nanoparticles with Checkpoint Small Interference RNAs (siRNA)

Small interference RNAs (siRNAs) are endogenous molecules that induce a variety of cellular responses. Although siRNA causes target mRNA to be degraded, it can also impede the translation of other slightly mismatched mRNAs when acting as miRNA.^{108,109} The delivery of siRNA to the target cell population in vivo is a challenge for siRNA-based cancer and other disorder therapies. For siRNA-based therapies to be successful in combating cancer, tumor cells must undergo potent and effective gene silencing. An ideal systemic siRNA delivery system should be biocompatible, eco-friendly, and non-immunogenic, protect siRNA from serum nucleases during circulation and release into endosomes, and avoid rapid hepatic or renal clearance.¹¹⁰ NPs have been proven to be effective carriers for the delivery of siRNA molecules. Due to the reduction of cytokine release, the interaction of PD-L1 on tumor cells with PD-1 on T cells may cause immune evasion, resulting in a weakened antitumor effect and metastasis.¹¹¹ As a result, specifically knocking down the expression of PD-L1 on tumor cells is a promising strategy. To load PD-L1 siRNA and the photosensitizer, Wang et al created 1,2-epoxytetradecane alkylated oligoethylenimine-containing (POP) hybrid micelles.¹¹²

Strategies Using Immune Checkpoint Inhibitors for Synergistic Cancer Therapy

Synergistic drugs based on ICB therapy have garnered interest in recent years and provided promising outcomes in tumor therapy, yet fundamental and clinical investigations of an immune checkpoint inhibitor (ICI)-based combination therapies are problematic. The selection of biocompatible and clinically appropriate DDSs is a main priority. The majority of magnetic nanostructure hydrogels, and particularly nanocarriers used in immune checkpoint blockade therapy-based synergistic therapy, contain a variety of organic and inorganic materials, including synthetic polymers and polymer-drug conjugates, altered natural polymers, and mesoporous silica, all of which have been proven to be “biocompatible” to some extent.¹¹³




Figure 4 Photoimmunotherapy for treatment of tumor and its metastasis by nanomaterials. Data from these studies.^{102–107}

Furthermore, the development of better DDSs intended to increase tumor targeting and lowering drug distribution in non-target organs should reduce immune-related adverse effects (irAEs) associated with ICIs (eg, integration of both chemotherapeutic drugs and ICIs in NPs). As a result, the clinical translation of synergistic therapies based on chemotherapy and radiation therapy in combination with ICB therapy is likely to be better and faster.¹¹⁴ Overall, ICI-based synergistic medications have broadened the “arsenal” of cancer treatment choices. The current research progress has provided a breakthrough for the future widespread use of ICI-based synergistic medications. In the fight against cancer, synergistic therapy based on ICIs will give doctors more alternatives and patients greater hope.¹¹³

The term “viral oncolysis” refers to the viral infection that causes the death of tumor cells.¹¹⁵ Oncolytic virus (OV) therapy has several benefits. Firstly, OVs can infect tumor cells and promote tumor lysis while avoiding the typical pathways of drug resistance.¹¹⁶ Secondly, viruses constitute an efficient treatment because they can proliferate in tumor cells and disseminate to neighboring tumor cells. Thirdly, many OVs can cause immunogenic death in the cells they infect. This boosts the host’s anti-cancer immunity by producing pathogen- and injury-related chemicals that encourage dendritic cells to present TAAs.¹¹⁷ More crucially, OVs and ICIs work in tandem to cause non-overlapping tumor cell toxicity. Their combined applications have exerted a significant impact on cancer treatment.¹¹⁸

Immunological adjuvants are auxiliary compounds that can be injected into the body simultaneously or before other treatments to avoid the body’s immune responses to those treatments.^{119,120} Interleukins (IL), as well as their activators and antagonists, are extensively employed as immunological adjuvants nowadays. In pancreatic cancer, for example, IL-6 has been demonstrated to induce immune CPB resistance.¹²¹ Liu et al revealed that IL-6 generated by cancer-associated fibroblasts promotes the advancement of hepatocellular carcinoma (HCC) by attracting immunosuppressive cells.^{122,123} As a result, they used IL-6 inhibitors in combination with a PD-L1 to treat HCC and achieved a favorable therapeutic response. Furthermore, local IL-12 buildup in the TME triggered the host’s adaptive immune activation. Fallon et al employed recombinant murine IL-12 in combination with a PD-L1, Avelumab, and found that the MC38 tumor was inhibited 70% of the time.¹²⁴

Customized nanoparticles functionalized with specific ligands are capable of reliably delivering encapsulated payloads to cancer cells.¹²⁵ Taking advantage of their nanoscale size and exceptional physicochemical characteristics, various nanomaterials have been developed, including carbon-based materials, liposomes, metallic nanoparticles, and dendrimers as effective DDS for cancer treatment. Additionally, they exhibit better pharmacokinetic and pharmacodynamic profiles over traditional formulations. Anticancer medications containing nanomaterials play an important role in cancer treatment. Current drug targeting and release strategies for effective cancer administration have been integrated with recent breakthroughs in nanomaterial engineering for improving cancer therapy. Although nanotoxicity is a mostly ignored aspect of nanotechnology, the side effects of NPs should be seriously considered.¹²⁶

Conclusion and Future Prospects

Combination therapy improves therapeutic results without increasing toxicity, improves efficacy, and overcomes medication resistance in cancer patients, assuring long-term treatment effectiveness. The advantages of employing nanoparticles with anticancer drugs in combination therapies include drug payloads, longer circulatory time in blood, lower dosage, and uniform, constant drug release. Nanoparticle-mediated combination therapy has numerous advantages, but also some drawbacks, including a lack of pertinent pre-clinical models for evaluating target efficacy and a gap in collaboration among different engineers, scientists, doctors, and pharmaceutical industries. Currently, CPIs are used in techniques for immune-mediated cancer cell clearance employing synergistic nanomedicines. Effective medical prospects for combination therapy with ICB inhibitors have been established due to the versatile and modular nature of NP synthesis.

Only a small number of medications based on nanomaterials are currently used in clinical settings despite the vast amount of research. In the future, more work needs to be done to reduce toxicity, illuminate the mechanism of protein corona, enhance permeability, and improve retention mechanisms in the human body. Nanoplatforms are being created to target not only cancer cells but also the tumor microenvironment. Additional research directions include improving nanomaterial targeting specificity, drug capacity, efficacy, and bioavailability, as well as lessening the toxicity of nanomaterials and loaded drugs toward normal cells. Practical approaches include using precise targeting methods, tumor microenvironment triggered release strategies, combined therapies, and self-assembly nanoplatforms. Another crucial area for research is testing nanomaterials in environments more similar to those seen *in vivo*.

Overall, we think that the growth of nanobiotechnology will help lead to more effective therapies and medications to effectively treat cancer.

Author Contributions

All authors made substantial contributions to the conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; agree to be accountable for all aspects of the work.

Funding

This research was supported by the Basic Research Program through the National Research Foundation of Korea (NRF) funded by the MSIT (NRF-2020R1A4A1016029).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Fitzmaurice C, Abate D, Abbasi N.; Collaboration GBoDC. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. *JAMA Oncol.* **2019**;5(12):1749–1768. doi:10.1001/jamaoncol.2019.2996
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.* **2020**;70(1):7–30.
3. Sawyers C. Targeted cancer therapy. *Nature.* **2004**;432(7015):294–297.
4. Lakshmanan V-K, Jindal S, Packirisamy G, et al. Nanomedicine-based cancer immunotherapy: recent trends and future perspectives. *Cancer Gene Ther.* **2021**;28(9):911–923.
5. Wang S, Sun Z, Hou Y. Engineering nanoparticles toward the modulation of emerging cancer immunotherapy. *Adv Healthc Mater.* **2021**;10(5):2000845.
6. Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PCW, Jin J-O. Cancer Immunotherapy by Immune Checkpoint Blockade and Its Advanced Application Using Bio-Nanomaterials. *Semin Cancer Biol.* **2022**; 86(Pt 2):909–922. doi:10.1016/j.semcancer.2022.02.01
7. Janssen LM, Ramsay EE, Logsdon CD, Overwijk WW. The immune system in cancer metastasis: friend or foe? *J Immunother Cancer.* **2017**;5(1):1–14.
8. Singh K, Yadav D, Jain M, Singh PK, Jin J-O. Immunotherapy for the breast cancer treatment: current evidence and therapeutic options. *Endocr Metab Immune Disord Drug Targets.* **2021**;22(2):212–224.
9. Yang Z, Ma Y, Zhao H, Yuan Y, Kim BY. Nanotechnology platforms for cancer immunotherapy. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* **2020**;12(2):e1590.
10. Jo SD, Nam G-H, Kwak G, Yang Y, Kwon IC. Harnessing designed nanoparticles: current strategies and future perspectives in cancer immunotherapy. *Nano Today.* **2017**;17:23–37. doi:10.1016/j.nantod.2017.10.008
11. Russell LM, Liu CH, Grodzinski P. Nanomaterials innovation as an enabler for effective cancer interventions. *Biomaterials.* **2020**;242:119926.
12. Hejmady S, Pradhan R, Alexander A, et al. Recent advances in targeted nanomedicine as promising antitumor therapeutics. *Drug Discov Today.* **2020**;25(12):2227–2244.
13. Jia R, Teng L, Gao L, et al. Advances in multiple stimuli-responsive drug-delivery systems for cancer therapy. *Int J Nanomedicine.* **2021**;16:1525.
14. Zhang C, Pu K. Molecular and nanoengineering approaches towards activatable cancer immunotherapy. *Chem Soc Rev.* **2020**;49(13):4234–4253.
15. Zhang C, Pu K. Recent progress on activatable nanomedicines for immunometabolic combinational cancer therapy. *Small Struct.* **2020**;1(2):2000026.
16. De Bousser E, Callewaert N, Festjens N, Cell Engaging T. Immunotherapies, highlighting Chimeric Antigen Receptor (CAR) T cell therapy. *Cancers.* **2021**;13(23):6067.
17. Su L, Chen G, Liu Z, Min Y, Wang AZ. Delivery strategies to overcome tumor immunotherapy resistance. In: *Systemic Drug Delivery Strategies*. Academic Press; **2022**:529–547.
18. Chuang ST, Conklin B, Stein JB, Pan G, Lee KB. Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications. *Nano Converg.* **2022**;9(1):1–31.
19. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. *Nat Rev Clin Oncol.* **2022**;19(4):254–267.
20. Buss CG, Bhatia SN. Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics. *Proc Natl Acad Sci U S A.* **2020**;117(24):13428–13436.
21. Mortezaee K, Majidpoor J. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives. *Medical Oncol.* **2022**;39(9):1–17.
22. Downs-Canner SM, Meier J, Vincent BG, Serody JS, Cell B. Function in the tumor microenvironment. *Annu Rev Immunol.* **2022**;40:169–193.
23. Huppert LA, Green MD, Kim L, et al. Tissue-specific tregs in cancer metastasis: opportunities for precision immunotherapy. *Cell Mol Immunol.* **2022**;19(1):33–45.
24. Biswas S, editor. *Tumor Microenvironment and Myelomonocytic Cells*. Rijeka: InTech; **2012**:1.

25. Shields CW, Evans MA, Wang LL-W, et al. Cellular backpacks for macrophage immunotherapy. *Sci Adv*. 2020;6(18):eaaz6579.
26. Di Somma S, Napolitano F, Portella G, Malfitano AM. Cross talk of macrophages with tumor microenvironment cells and modulation of macrophages in cancer by virotherapy. *Biomedicines*. 2021;9(10):1309.
27. Xu Z, Chen Y, Ma L, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. *Mol Ther*. 2022;30:3133–3154.
28. Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. *Br J Cancer*. 2019;120(1):16–25.
29. Srivastava MK, Zhu L, Harris-White M, et al. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. *Immuno Targets Ther*. 2012;1:7.
30. Song W, Das M, Chen X. Nanotherapeutics for immuno-oncology: a crossroad for new paradigms. *Trends Cancer*. 2020;6(4):288–298.
31. Filli MS, Ibrahim AA, Aquib M, et al. The impact of physicochemical characteristics on therapeutic efficacy of anticancer nanomaterials: a review. *Int J Pharm Sci Drug Res*. 2019;11:61–70.
32. Chauhan PS, Yadav D, Koul B, Mohanta YK, Jin J-O. Recent advances in nanotechnology: a novel therapeutic system for the treatment of Alzheimer's disease. *Curr Drug Metab*. 2020;21(14):1144–1151.
33. Chauhan PS, Yadav D, Tayal S, Jin J-O. Therapeutic advancements in the management of diabetes mellitus with special reference to nanotechnology. *Curr Pharm Des*. 2020;26(38):4909–4916.
34. Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. *J Nanobiotechnology*. 2018;16(1):1–33.
35. Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. *Biomater Res*. 2019;23(1):20.
36. Wang J, Li Y, Nie G. Multifunctional biomolecule nanostructures for cancer therapy. *Nature Rev Mater*. 2021;6(9):766–783.
37. Gao W, Hu C-MJ, Fang RH, Zhang L. Liposome-like nanostructures for drug delivery. *J Mater Chem B Mater Biol Med*. 2013;1(48):6569–6585.
38. Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. *Int J Pharm*. 2021;601:120571.
39. Guimarães D, Lager F, Renault G, et al. Folate-Targeted Liposomal Formulations Improve Effects of Methotrexate in Murine Collagen-Induced Arthritis. *Biomedicines*. 2022;10(2):229.
40. Gagliardi A, Giuliano E, Venkateswararao E, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. *Front Pharmacol*. 2021;12:601626.
41. El-Say KM, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. *Int J Pharm*. 2017;528(1–2):675–691.
42. Choudhary S, Gupta L, Rani S, Dave K, Gupta U. Impact of dendrimers on solubility of hydrophobic drug molecules. *Front Pharmacol*. 2017;8:261.
43. Caminade AM, Turrin CO. Dendrimers for drug delivery. *J Mater Chem B*. 2014;2(26):4055–4066.
44. Alli S, Kumar Vemula S, Reddy Veerareddy P. Role of microspheres in drug delivery-an overview. *Drug Deliv Lett*. 2013;3(3):191–199.
45. Singh C, Purohit S, Singh M, Pandey B. Design and evaluation of microspheres: a Review. *Jddr*. 2013;2(2):18–27.
46. Farooq MU, Novosad V, Rozhkova EA, et al. Gold nanoparticles-enabled efficient dual delivery of anticancer therapeutics to HeLa cells. *Sci Rep*. 2018;8(1):1–12.
47. Yafout M, Ousaid A, Khayati Y, El Otmani IS. Gold nanoparticles as a drug delivery system for standard chemotherapeutics: a new lead for targeted pharmacological cancer treatments. *Sci Afr*. 2021;11:e00685.
48. Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. *J Nanomater*. 2019;2019. doi:10.1155/2019/3702518
49. Maiti D, Tong X, Mou X, Yang K. Carbon-based nanomaterials for biomedical applications: a recent study. *Front Pharmacol*. 2019;9:1401.
50. Chandrakala V, Aruna V, Angajala G. Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems. *Emergent Mater*. 2022;5:1593–1615.
51. Iqbal MT, Halasz K, Bhatia D. Metallic nanoparticles for targeted drug delivery. *NMCT*. 2017;1:3–5.
52. Zhang Y, Huang Y, Li S. Polymeric micelles: nanocarriers for cancer-targeted drug delivery. *AAPS Pharm Sci Tech*. 2014;15(4):862–871.
53. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. *J Drug Deliv*. 2013;2013:340315.
54. Ahmad Z, Shah A, Siddiq M, Kraatz H-B. Polymeric micelles as drug delivery vehicles. *RSC Adv*. 2014;4(33):17028–17038.
55. Shi Z, Zhou Y, Fan T, Lin Y, Zhang H, Mei L. Inorganic nano-carriers based smart drug delivery systems for tumor therapy. *Smart Mater Med*. 2020;1:32–47.
56. Hu J, Wang J, Wang G, Yao Z, Dang X. Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells. *Int J Mol Med*. 2016;37(3):690–702.
57. Nakhai P, Margiana R, Bokov DO, et al. Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. *Front Bioeng Biotechnol*. 2021;9:748.
58. Bozzuto G, Molinari A. Liposomes as nanomedical devices. *Int J Nanomedicine*. 2015;10:975–999.
59. Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. *Nanomedicine*. 2013;8(9):1509–1528.
60. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. *Front Pharmacol*. 2015;6:286.
61. Glassman PM, Muzykantov VR. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. *J Pharmacol Exp Ther*. 2019;370(3):570–580.
62. Gurunathan S, Kang M-H, Qasim M, Kim J-H. Nanoparticle-mediated combination therapy: two-in-one approach for cancer. *Int J Mol Sci*. 2018;19(10):3264.
63. Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. *Arab J Chem*. 2019;12(7):908–931.
64. Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. *Mater Sci Eng C Mater Biol Appl*. 2016;60:569–578.

65. Majumder N, Das GN, Das SK. Polymeric micelles for anticancer drug delivery. *Ther Deliv*. 2020;11(10):613–635.
66. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. *Front Pharmacol*. 2014;5:77.
67. Movassaghian S, Merkel OM, Torchilin VP. Applications of polymer micelles for imaging and drug delivery. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2015;7(5):691–707.
68. Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. *Nanoscale Res Lett*. 2014;9(1):247.
69. Franiak-Pietryga I, Ziemia B, Sikorska H, et al. Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL. *Toxicol Appl Pharmacol*. 2020;403:115139.
70. Varde NK, Pack DW. Microspheres for controlled release drug delivery. *Expert Opin Biol Ther*. 2004;4(1):35–51.
71. Rauti R, Musto M, Bosi S, Prato M, Ballerini L. Properties and behavior of carbon nanomaterials when interfacing neuronal cells: how far have we come? *Carbon N Y*. 2019;143:430–446.
72. Gurunathan S, Han JW, Dayem AA, Eppakayala V, Kim JH. Oxidative stress-mediated antibacterial activity of graphene oxide and reduced graphene oxide in *Pseudomonas aeruginosa*. *Int J Nanomedicine*. 2012;7:5901–5914.
73. Sarkar P, Ghosal K, Chakraborty D, Sarkar K. Chapter 20 - Biocompatibility and biomedical applications of various carbon-based materials. In: Thomas S, Sarathchandran C, Ilangoan SA, Moreno-Piraján JC, editors. *Handbook of Carbon-Based Nanomaterials*. Elsevier; 2021:829–875.
74. Debnath SK, Srivastava R. Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects. *Front Nanotechnol*. 2021;3:644564.
75. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. *Pharmacol Rep*. 2012;64(5):1020–1037.
76. Mody VV, Cox A, Shah S, Singh A, Bevins W, Parihar H. Magnetic nanoparticle drug delivery systems for targeting tumor. *Appl Nanosci*. 2014;4(4):385–392.
77. Iram S, Zahera M, Khan S, et al. Gold nanoconjugates reinforce the potency of conjugated cisplatin and doxorubicin. *Colloids Surf B Biointerfaces*. 2017;160:254–264.
78. Kollur SP, Prasad SK, Pradeep S, et al. Luteolin-fabricated ZnO nanostructures showed PLK-1 mediated anti-breast cancer activity. *Biomolecules*. 2021;11(3):385.
79. Kumari M, Sharma N, Manchanda R, et al. PGMD/curcumin nanoparticles for the treatment of breast cancer. *Sci Rep*. 2021;11(1):1–17.
80. Sharma N, Singhal M, Kumari RM, et al. Diosgenin loaded polymeric nanoparticles with potential anticancer efficacy. *Biomolecules*. 2020;10(12):1679.
81. Sharma N, Kumari RM, Gupta N, Syed A, Bahkali AH, Nimesh S. Poly-(lactic-co-glycolic) acid nanoparticles for synergistic delivery of epirubicin and paclitaxel to human lung cancer cells. *Molecules*. 2020;25(18):4243.
82. Kishimoto TK, Maldonado RA. Nanoparticles for the induction of antigen-specific immunological tolerance. *Front Immunol*. 2018;9:230.
83. Thorp EB, Boada C, Jarbath C, Luo X. Nanoparticle platforms for antigen-specific immune tolerance. *Front Immunol*. 2020;11:945.
84. Yang R, Xu J, Xu L, et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. *ACS Nano*. 2018;12(6):5121–5129.
85. Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. *Cell*. 2018;174(4):1031–1032.
86. Wu C-C, Wang YA, Livingston JA, Zhang J, Futreal PA. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. *Nat Commun*. 2022;13(1):1–14.
87. Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. *Redox Biol*. 2019;25:101174.
88. Li Y, Bolinger J, Yu Y, et al. Intracellular delivery and biodistribution study of CRISPR/Cas9 ribonucleoprotein loaded bioreducible lipidoid nanoparticles. *Biomater sci*. 2019;7(2):596–606.
89. Kuang X, Wang Z, Luo Z, et al. Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma. *J Colloid Interface Sci*. 2022;616:189–200.
90. Chen W, Jiang M, Yu W, et al. CpG-based nanovaccines for cancer immunotherapy. *Int J Nanomedicine*. 2021;16:5281–5299.
91. Habault J, Poyet J-L. Recent advances in cell penetrating peptide-based anticancer therapies. *Molecules*. 2019;24(5):927.
92. Dacoba TG, Anfray C, Mainini F, et al. Arginine-based Poly(I:C)-loaded nanocomplexes for the polarization of macrophages toward M1-antitumoral effectors. *Front Immunol*. 2020;11:1412.
93. Abudula T, Bhatt K, Eggermont LJ, O'Hare N, Memic A, Bencherif SA. Supramolecular self-assembled peptide-based vaccines: current state and future perspectives. *Front Chem*. 2020;8:598160.
94. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. *Blood*. 1997;89(8):2994–2998.
95. Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. *NAR Cancer*. 2020;2(1):zcaa002.
96. Gupta B, Kim JO. Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices. *J Pharmaceut Invest*. 2021;51(4):399–412.
97. Duwa R, Jeong J-H, Yook S. Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction. *J Industr Enginer Chem*. 2021;94:62–77.
98. Wang C, Wang J, Zhang X, et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. *Sci Transl Med*. 2018;10:429.
99. Min Y, Roche KC, Tian S, et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. *Nat Nanotechnol*. 2017;12(9):877–882.
100. Peng Z, Lv X, Huang S. Photoimmunotherapy: a New Paradigm in Solid Tumor Immunotherapy. *Cancer Control*. 2022;29:10732748221088825. doi:10.1177/10732748221088825
101. Guo R, Wang S, Zhao L, et al. Engineered nanomaterials for synergistic photo-immunotherapy. *Biomaterials*. 2022;282:121425. doi:10.1016/j.biomaterials.2022.121425
102. Hwang J, An E-K, Zhang W, et al. Recombinant programmed cell death protein 1 functions as an immune check point blockade and enhances anti-cancer immunity. *Biomaterials*. 2022;285:121550. doi:10.1016/j.biomaterials.2022.121550

103. Hwang J, An E-K, Zhang W, Kim HJ, Eom Y, Jin J-O. Dual-functional alginate and collagen-based injectable hydrogel for the treatment of cancer and its metastasis. *J Nanobiotechnology*. 2022;20(1):1–16. doi:10.1186/s12951-022-01458-x
104. Hwang J, An E-K, Kim S-J, Zhang W, Jin J-O. Escherichia coli mimetic gold nanorod-mediated photo-and immunotherapy for treating cancer and its metastasis. *ACS nano*. 2022;16(5):8472–8483. doi:10.1021/acsnano.2c03379
105. Hwang J, Zhang W, Park H-B, Yadav D, Jeon YH, Jin J-O. Escherichia coli adhesin protein-conjugated thermal responsive hybrid nanoparticles for photothermal and immunotherapy against cancer and its metastasis. *J Immunother Cancer*. 2021;9(7):e002666. doi:10.1136/jitc-2021-002666
106. Xu L, Zhang W, Park H-B, et al. Indocyanine green and poly I: c containing thermo-responsive liposomes used in immune-photothermal therapy prevent cancer growth and metastasis. *J Immunother Cancer*. 2019;7(1):1–14. doi:10.1186/s40425-019-0702-1
107. Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. *Nat Commun*. 2016;7(1):13193. doi:10.1038/ncomms13193
108. Devi GR. siRNA-based approaches in cancer therapy. *Cancer Gene Ther*. 2006;13(9):819–829. doi:10.1038/sj.cgt.7700931
109. Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA versus miRNA as therapeutics for gene silencing. *Mol Ther Nucleic Acids*. 2015;4(9):e252–e252.
110. Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. *Artif Cells, Nanomed Biotechnol*. 2018;46(2):274–283.
111. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012;12(4):252–264.
112. Wang D, Wang T, Liu J, et al. Acid-activatable versatile micelleplexes for PD-L1 blockade-enhanced cancer photodynamic immunotherapy. *Nano Lett*. 2016;16(9):5503–5513.
113. He M, Yang T, Wang Y, et al. Immune checkpoint inhibitor-based strategies for synergistic cancer therapy. *Adv Healthc Mater*. 2021;10(9):2002104.
114. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. *Cancer Immunol Res*. 2015;3(5):436–443.
115. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. *Nat Rev Cancer*. 2005;5(12):965–976.
116. Lin E, Nemunaitis J. Oncolytic viral therapies. *Cancer Gene Ther*. 2004;11(10):643–664.
117. Yin J, Markert JM, Leavenworth JW. Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapy. *Front Oncol*. 2017;7:136.
118. Bommarreddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. *Sci Transl Med*. 2018;10(471):eaau0417.
119. Allison AC. Immunological adjuvants and their modes of action. *Arch Immunol Ther Exp*. 1997;45(2–3):141–147.
120. Awate S, Babiuk L, Mutwiri G. Mechanisms of Action of adjuvants. *Front Immunol*. 2013;4. doi:10.3389/fimmu.2013.00114
121. Mace TA, Shakya R, Pitarresi JR, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. *Gut*. 2018;67(2):320–332.
122. Liu T, Han C, Wang S, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. *J Hematol Oncol*. 2019;12(1):86.
123. Wu X, Tao P, Zhou Q, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. *Oncotarget*. 2017;8(13):20741–20750.
124. Fallon JK, Vandeveer AJ, Schlom J, Greiner JW. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. *Oncotarget*. 2017;8(13):20558–20571.
125. Vaughan HJ, Green JJ, Tzeng SY. Cancer-targeting nanoparticles for combinatorial nucleic acid delivery. *Adv Mater*. 2020;32(13):e1901081.
126. Navya PN, Kaphe A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. *Nano Converg*. 2019;6(1):23.

International Journal of Nanomedicine

Dovepress

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-nanomedicine-journal>